Navigation Links
CryoLife Announces Release Date and Teleconference Call Details for 2009 Second Quarter Financial Results

ATLANTA, July 13 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY),an implantable biological medical device and cardiovascular tissue processing company,announced today that 2009 second quarter financial results will be released on Thursday, July 30, 2009. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive officer of CryoLife, Inc.

To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 10:00 a.m. A replay of the teleconference will be available July 30 through August 7 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The account number for the replay is 244 and the conference number is 327576.

The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife Web site at and selecting the heading Webcasts & Presentations.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. The Company's CryoValve((R)) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft((R)) technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed or malfunctioning native pulmonary valves. The Company's BioGlue((R)) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. BIOGLUE Aesthetic(TM) Medical Adhesive is CE marked in the European Community for periosteal fixation following endoscopic browplasty (brow lift) in reconstructive plastic surgery and is distributed by a third party for this indication. CryoLife distributes HemoStase(TM), a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the European Community and Canada for cardiac, vascular, and general surgery, subject to certain exclusions.

For additional information about the company, visit CryoLife's Web site:

    Media Contacts:

    D. Ashley Lee                               Katie Brazel
    Executive Vice President, Chief Financial   Fleishman Hillard
    Officer and Chief Operating Officer         Phone: 404-739-0150
    Phone: 770-419-3355

SOURCE CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Department of Defense Awards CryoLife $1.7 million to Develop BioFoam Hemostatic Technology
2. CryoLife Announces Release Date and Teleconference Call Details for First Quarter 2008 Financial Results
3. William F. Northrup, III, M.D. Joins CryoLife as Vice President of Medical Relations and Education
4. Cryolife Victim Responds to Untrue Assertions of Cryolife
5. CryoLife Announces Additions to Management Team
6. Victory Pharma, Inc. Announces FDA Accepts MGX006 NDA for Review
7. Uroplasty Announces Patent Issuance Related to the Urgent(R) PC System
8. ONRAD Announces its "Name Our Ant" Competition
9. U.S. Non-Profit Announces Opening of Life-Saving Dialysis Facility in Philippines
10. Pederson Immigration Law Group Announces 14th Annual J-1/H-1B Foreign Physician Immigration Conference and Job Fair Series
11. CBCA Administrators, Inc. Announces Partnership with Bravo Wellness
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... – Kreithen”), one of the leading plastic surgery practices in Florida, is proud ... chosen to consult for surgical innovations giant Ethicon Inc., a Johnson & Johnson ...
(Date:11/30/2015)... ... November 30, 2015 , ... The successful filing of an Investigational New ... is so important to this key industry segment, Regis Technologies has decided to sponsor ... December 4th at 11am EST. , Federal law does not allow new drugs to ...
(Date:11/30/2015)... ... November 30, 2015 , ... Healthjump, Inc. announced ... a Healthcare IT consulting, development and support company. The purchase will expand the ... within DataTrade to extend the services currently provided by Healthjump. , ...
(Date:11/30/2015)... ... , ... GKhair & Tibolli team members and artists were excited and proud ... 8th and 9th at the Puerto Rico Convention Center, San Juan Puerto Rico. The ... of the line fashion journalists. The San Juan Beauty Show carries immense credibility among ...
(Date:11/30/2015)... Georgia (PRWEB) , ... November 30, 2015 , ... ... for healthcare professionals worldwide today released the results of a survey of educational ... East and Africa found a growing global demand for high quality online and ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... LONDON and BOSTON , ... to research and develop potential new medicines directed at ... multiple therapeutic areas. --> PFE ) to ... to 10 G protein-coupled receptor (GPCR) targets across multiple ... clinical-stage GPCR structure-guided drug discovery and development company and ...
(Date:11/30/2015)... Israel , Nov. 30, 2015  OticPharma, ... acquiring and developing innovative therapies for ear, nose, and ... Keith A. Katkin as chairman of the company,s ... chief executive officer for OticPharma, Ltd.  "Keith brings a ... he will be able to share this experience and ...
(Date:11/30/2015)... SHELTON, Connecticut , November 30, 2015 ... Kentucky Breast Care has entered into a ... women,s healthcare practice. This will allow Kentucky Breast Care ... and offer exceptional care for their patients. ... Kentucky Breast Care has entered into a ...
Breaking Medicine Technology: